| 13.07 0.07 (0.54%) | 08-05 19:34 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.21 | 1-year : | 18.93 |
| Resists | First : | 13.88 | Second : | 16.21 |
| Pivot price | 12.58  |
|||
| Supports | First : | 10.57 | Second : | 8.53 |
| MAs | MA(5) : | 13.01 |
MA(20) : | 11.91 |
| MA(100) : | 11.38 |
MA(250) : | 6.45 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 82.9  |
D(3) : | 86.2 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 17.25 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ANL ] has closed below upper band by 29.9%. Bollinger Bands are 44.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.36 - 13.41 | 13.41 - 13.47 |
| Low: | 12.77 - 12.83 | 12.83 - 12.89 |
| Close: | 12.97 - 13.06 | 13.06 - 13.16 |
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Mon, 03 Aug 2026
Adlai Nortye (NASDAQ: ANL) secures ethics nod for AN4035 Phase I cancer trial - Stock Titan
Sat, 01 Aug 2026
Adlai Nortye Ltd. Revenue Breakdown – NASDAQ:ANL - TradingView
Fri, 31 Jul 2026
Adlai Nortye: AN9025 Still Needs Human Validation (NASDAQ:ANL) - Seeking Alpha
Mon, 27 Jul 2026
Adlai Nortye Ltd (ANL) Income Statement - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 15.9 (%) |
| Shares Short | 3,520 (K) |
| Shares Short P.Month | 3,330 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.21 |
| Profit Margin | 0 % |
| Operating Margin | -330.5 % |
| Return on Assets (ttm) | -42.3 % |
| Return on Equity (ttm) | -414.1 % |
| Qtrly Rev. Growth | 178.1 % |
| Gross Profit (p.s.) | 0.08 |
| Sales Per Share | 0.08 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -11.78 |
| PEG Ratio | 0 |
| Price to Book value | -62.24 |
| Price to Sales | 153.52 |
| Price to Cash Flow | -22.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|